Monthly information on share capital and company voting rights
Rhea-AI Summary
Cellectis (Euronext Growth: CLLS) published its monthly information on share capital and voting rights as of 09/30/2025. The company reports a total number of shares of 100,325,229 and a total number of voting rights of 89,413,272. The disclosure follows Article 223-16 of the General Regulation of the French financial markets authority and lists investor and media contacts for further information.
Positive
- None.
Negative
- None.
News Market Reaction 16 Alerts
On the day this news was published, CLLS gained 20.13%, reflecting a significant positive market reaction. Our momentum scanner triggered 16 alerts that day, indicating notable trading interest and price volatility. The stock closed at $4.59 on that trading session. This price movement added approximately $56M to the company's valuation, bringing the market cap to $332M at that time. Trading volume was elevated at 2.2x the daily average, suggesting notable buying interest.
Data tracked by StockTitan Argus on the day of publication.
(Article 223-16 of General Regulation of the French financial markets authority)
PARIS, Oct. 07, 2025 (GLOBE NEWSWIRE) --
Listing market: Euronext Growth
ISIN code: FR0010425595
| Date | Total number of shares in the capital | Total number of voting rights |
| 09/30/2025 | 100,325,229 | 89,413,272 |
For further information on Cellectis, please contact:
Media contacts:
Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, media@cellectis.com
Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93
Investor Relations contact:
Arthur Stril, Chief Financial Officer & Chief Business Officer, investors@cellectis.com
Attachment